Is a complete ABOS research report available?

No complete published report is available for Acumen Pharmaceuticals, Inc. (ABOS) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Acumen Pharmaceuticals, Inc. (ABOS)

NASDAQ: ABOS · USD

$2.17

+0.06 (+2.8%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-31 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first ABOS analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	156.7M
Net income (ttm)	-113.3M
EPS (ttm)	-$1.85
Shares out	72.2M
Volume	333,327
Beta	0.34
Price target	$7.40	+241.0%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -113.3M
EPS (ttm): -$1.85
Market cap: 156.7M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All ABOS indicators

Market & fundamental data

Available fields

184

Groups with data

Currency

USD

Showing 184 of 184 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001576885
Company name	Acumen Pharmaceuticals, Inc.
Country	United States
Country code	US
Cusip	00509G209
Employees	61
Employees Change	9%
Employees Change Percent	17.31
Enterprise value	$59.5M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2021-07-01
Isin	US00509G2093
Last refreshed	2026-07-31
Market cap	$156.7M
Market cap category	Micro-Cap
Price	$2.17
Price currency	USD
Sector	Healthcare
Sector PE	45.64
Sector PE Fwd	24.21
Sic	2836
Symbol	ABOS
Website	https://acumenpharm.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-72.27%
FCF yield	-67.35%
P/B ratio	1.79x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross Profit	$-104.9M
Net Income	$-113.3M
Net Income Growth Quarters	3%
Net Income Growth Years	0%
Profit Per Employee	$-1.9M
ROA	-42.37
Roa5y	-21.19
ROCE	-109.8
ROE	-93.23
Roe5y	-52.39
ROIC	-47.14

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	57.3%
Cagr3y	-33.35%
Cagr5y	-32.36%
EPS Growth Quarters	3
EPS Growth Years	0
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$133.6M
Cash	$128.4M
Current Assets	$133.1M
Current Liabilities	$29.2M
Debt	$31.2M
Debt Equity	$0.36
Equity	$87.5M
Interest Coverage	-26.84
Liabilities	$46.2M
Long Term Assets	$535,000
Long Term Liabilities	$16.9M
Net Cash	$97.2M
Net Cash By Market Cap	$62.04
Net Cash Growth	-42.18%
Net Debt Equity	$-1.11
Tangible Book Value	$87.5M
Tangible Book Value Per Share	$1.21
WACC	6.91

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	4.55
Net Working Capital	$-10.3M
Quick ratio	4.43
Working Capital	$103.9M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-1.73%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	57.25%
200-day SMA	2.35
3Y total return	-70.4%
50-day SMA	2.38
50-day SMA vs 200-day SMA	50over200
5Y total return	-85.84%
All Time High	26.98
All Time High Change	-91.96%
All Time High Date	2021-07-01
All Time Low	0.86
All Time Low Change	153.77%
All Time Low Date	2025-04-21
ATR	0.16
Beta	0.34
Beta1y	2.25
Beta2y	2.42
Ch YTD	2.84
High	2.19
High52	3.6
High52 Date	2026-03-16
High52ch	-39.72%
Low	2.1
Low52	1.19
Low52 Date	2025-08-12
Low52ch	82.35%
Ma50ch	-8.82%
Price vs 200-day SMA	-7.78%
RSI	42.83
RSI Monthly	46.03
RSI Weekly	46.88
Sharpe ratio	0.89x
Sortino ratio	1.62
Total Return	-1.73%
Tr YTD	2.84
Tr1m	-21.66%
Tr3m	-7.26%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	6
Analyst Count Top	3
Analyst Price Target Top	$6.67
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.4
Operating Income	$-114.6M
Price target	$7.4
Price Target Change	$241
Price Target Change Top	$207

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	36,956,181%
Float Percent	51.17%
Shares Insiders	14.62%
Shares Institutions	32.82%
Shares Out	72,227,580
Shares Qo Q	4.37%
Shares Yo Y	1.73%
Short Float	7.62%
Short Ratio	3.97
Short Shares	3.9

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-115.3M
Adjusted OCF	-115,319,000
Average Volume	376,958.05x
Bv Per Share	1.21
CAPEX	$-9,000
Ch1m	-21.66
Ch1y	57.25
Ch3m	-7.26
Ch3y	-70.4
Ch5y	-85.84
Ch6m	-22.22
Change	2.84%
Change From Open	2.36
Close	2.11
Days Gap	0.47
Depreciation Amortization	55,000
Dollar Volume	723,319.6
Earnings Date	2026-08-11
Earnings Time	bmo
EBIT	$-114.6M
EBITDA	$-114.4M
EPS	$-1.85
F Score	2
FCF	$-105.6M
FCF EV Yield	-177.41x
FCF Per Share	$-1.46
Financing CF	35,744,000
Fiscal Year End	December
Founded	1,996
Investing CF	91,437,000
Ipr	-86.44
Iprfo	-91.34
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-12
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-03-26
Ma150	2.48
Ma150ch	-12.36%
Ma20	2.38
Ma20ch	-8.75%
Net CF	21,636,000
Next Earnings Date	2026-08-11
Open	2.12
Optionable	Yes
Position In Range	77.78
Post Close	2.17
Postmarket Change Percent	2.3
Postmarket Price	$2.22
Ppne	197,000
Price Date	2026-07-30
Ptbv Ratio	1.79
Relative Volume	0.88x
Share Based Comp	9,774,000
Tr6m	-22.22%
Us State	Massachusetts
Volume	333,327

Acumen Pharmaceuticals, Inc. (ABOS)

Coverage state: Market snapshot only — no published research

Generate the first ABOS analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · ABOS

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All ABOS indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on ABOS

Frequently asked questions